Product Description
Sapanisertib is a dual TORC 1/2 inhibitor that targets a key survival mechanism in KEAP1/NRF2-mutated tumor cells. These mutations are found in a considerable sub-population of patients across multiple solid tumor types. (Sourced from: https://www.calithera.com/mtorc1-2-inhibitor-sapanisertib-cb-228/)
Mechanisms of Action: mTOR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - Lung Cancer *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 2: Anaplastic Thyroid Carcinoma|Endometrial Cancer|Renal Cell Carcinoma|Thyroid Cancer|Transitional Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
FTH-PIK-201 | P2 |
Not yet recruiting |
Endometrial Cancer |
2028-09-01 |
57% |
FTH-PIK-201 | P2 |
Not yet recruiting |
Endometrial Cancer |
2028-09-01 |
57% |
NCT02244463 | P2 |
Completed |
Thyroid Cancer|Anaplastic Thyroid Carcinoma |
2022-04-28 |
|
NCT03097328 | P2 |
Completed |
Renal Cell Carcinoma |
2021-07-20 |
|
2017-004486-27 | P2 |
Completed |
Transitional Cell Carcinoma |
2021-04-15 |